The new formulation of the drug that was tested in the trial used Halozyme Therapeutics' proprietary technology, which allows large volumes of Opdivo, currently administered intravenously, to be delivered as an injection under the skin. "We believe this new option, given as a single injection administered in less than five minutes, could transform the treatment experience for both patients and physicians," Gina Fusaro, an executive at Bristol Myers Squibb, said.